The Questions on Everyone’s Mind: What is and Why Do We Need Preventive Cardiology?
By: Tahir Mahmood and Michael D. Shapiro
References
- Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021 Feb 23;143(8):e254–e743. doi: 10.1161/CIR.0000000000000950
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Sep 10;74(10):e177–e232. doi: 10.1016/j.jacc.2019.03.010
- Johnson NB, Hayes LD, Brown K, Hoo EC, Ethier KA, Centers for Disease Control and Prevention (CDC). CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors—United States, 2005-2013. MMWR Suppl. 2014 Oct 31;63(4): 3–27.
- Pantalone KM, Hobbs TM, Chagin KM, et al. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. BMJ Open. 2017 Nov 16;7(11):
e017583 . doi: 10.1136/bmjopen-2017-017583 - Mattar A, Carlston D, Sariol G, et al. The prevalence of obesity documentation in Primary Care Electronic Medical Records. Are we acknowledging the problem? Appl Clin Inform. 2017 Jan 25;8(1):67–79. doi: 10.4338/ACI-2016-07-RA-0115
- Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec;34(45):3478–90a. doi: 10.1093/eurheartj/eht273
- Wilemon KA, Patel J, Aguilar-Salinas C, et al. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action. JAMA Cardiol. 2020 Feb 1;5(2):217–229. doi: 10.1001/jamacardio.2019.5173
- Shapiro MD, Maron DJ, Morris PB, et al. Preventive Cardiology as a Subspecialty of Cardiovascular Medicine: JACC Council Perspectives. J Am Coll Cardiol. 2019 Oct 15;74(15):1926–1942. doi: 10.1016/j.jacc.2019.08.1016
- Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007 Jun 7;356(23):2388–98. doi: 10.1056/NEJMsa053935
- Keeney T, Fox AB, Jette DU, Jette A. Functional Trajectories of Persons with Cardiovascular Disease in Late Life. J Am Geriatr Soc. 2019 Jan;67(1):37–42. doi: 10.1111/jgs.15584
- Lopez AD, Adair T. Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. Int J Epidemiol. 2019 Dec 1;48(6):1815–1823. doi: 10.1093/ije/dyz143
- Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world—a growing challenge. N Engl J Med. 2007 Jan 18;356(3):213–5. doi: 10.1056/NEJMp068177
- Schultz WM, Kelli HM, Lisko JC, et al. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions. Circulation. 2018 May 15;137(20):2166–2178. doi: 10.1161/CIRCULATIONAHA.117.029652
- Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020 Sep;17(9):543–558. doi: 10.1038/s41569-020-0413-9
- Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart. 2021 Mar;107(5):373–380. doi: 10.1136/heartjnl-2020-317901
- CDC.gov [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; c2021. Medical Conditions; 2021 Aug 20 [cited 2021 Aug 30]. Available from:
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html - Sperling LS. The Future of Cardiovascular Prevention: Unprecedented Times. Circulation. 2020 Jun 16;141(24):1946–1947. doi: 10.1161/CIRCULATIONAHA.120.047059
- Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014 Mar 15;383(9921):999–1008. doi: 10.1016/S0140-6736(13)61752-3
- Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J
3rd . Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study. Ann Intern Med. 1961 Jul;55:33–50. doi: 10.7326/0003-4819-55-1-33 - Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. 1998 May 12;97(18):1837–47. doi: 10.1161/01.cir.97.18.1837
- Goff DC
Jr , Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S49–73. doi: 10.1161/01.cir.0000437741.48606.98 - The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984 Jan 20;251(3):351–64. doi: 10.1001/jama.1984.03340270029025
- The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984 Jan 20;251(3): 365–74
- Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 Dec;8(6):1245–55. doi: 10.1016/s0735-1097(86)80293-5
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383–9.
- Steinberg D. The statins in preventive cardiology. N Engl J Med. 2008 Oct 2;359(14):1426–7. doi: 10.1056/NEJMp0806479
- Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015 Jun 18;372(25):2387–97. doi: 10.1056/NEJMoa1410489
- Mahmood T, Shapiro MD. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology. Curr Opin Cardiol. 2019 Sep;34(5):519–525. doi: 10.1097/HCO.0000000000000657
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017 May 4;376(18):1713–1722. doi: 10.1056/NEJMoa1615664
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097–2107. doi: 10.1056/NEJMoa1801174
- Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017 Oct 28;390(10106):1962–1971. doi: 10.1016/S0140-6736(17)32290-0
- Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med. 2020 May 13;7:88. doi: 10.3389/fcvm.2020.00088
- Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017 Feb;14(2):135–150. doi: 10.11909/j.issn.1671-5411.2017.02.008
- Aragam KG, Natarajan P. Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications. Circ Res. 2020 Apr 24;126(9):1159–1177. doi: 10.1161/CIRCRESAHA.120.315928
- Aragam KG, Dobbyn A, Judy R, et al. Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease. J Am Coll Cardiol. 2020 Jun 9;75(22):2769–2780. doi: 10.1016/j.jacc.2020.04.027
- Fazio S, Shapiro MD. PREVENTIVE CARDIOLOGY AS NEW SUBSPECIALTY OF CARDIOVASCULAR MEDICINE. Trans Am Clin Climatol Assoc. 2020;131:33–41
- Nambi V, Deswal A, Ballantyne CM. Prevention of “Failure”: Is It a Failure of Prevention? Circulation. 2018 Jan 9;137(2):106–108. doi: 10.1161/CIRCULATIONAHA.117.030645
- Du X, Dong J, Ma C. Is Atrial Fibrillation a Preventable Disease? J Am Coll Cardiol. 2017 Apr 18;69(15):1968–1982. doi: 10.1016/j.jacc.2017.02.020
- Eckel RH, Blaha MJ. Cardiometabolic Medicine: A Call for a New Subspeciality Training Track in Internal Medicine. Am J Med. 2019 Jul;132(7):788–790. doi: 10.1016/j.amjmed.2019.02.027
- Warden BA, Shapiro MD, Fazio S. The Role of the Clinical Pharmacist in a Preventive Cardiology Practice. Ann Pharmacother. 2019 Dec;53(12):1214–1219. doi: 10.1177/1060028019864669
- Kaufman TM, Duell PB, Purnell JQ, Wójcik C, Fazio S, Shapiro MD. Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities. Circ Res. 2017 Aug 18;121(5):499–501. doi: 10.1161/CIRCRESAHA.117.311532
- Kaufman TM, Warden BA, Minnier J, et al. Application of PCSK9 Inhibitors in Practice. Circ Res. 2019 Jan 4;124(1):32–37. doi: 10.1161/CIRCRESAHA.118.314191
DOI: https://doi.org/10.14797/mdcvj.698 | Journal eISSN: 1947-6108
Language: English
Page range: 8 - 14
Submitted on: Mar 24, 2021
Accepted on: Jun 25, 2021
Published on: Sep 24, 2021
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
Keywords:
© 2021 Tahir Mahmood, Michael D. Shapiro, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.